The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment.

J Immunother Cancer · 2017 · PMC5557252 · PMID 28807001

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Treatment with selumetinib for 4 days, followed by 3 days off-treatment, resulted in a small increase in the overall KLH-specific IFNγ production to 949 ± 255 pg/mL but did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.